Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell–mediated antibody-dependent cellular cytotoxicity

Blood

Volumn 121, Issue 23, 2013, Pages 4694-4702

  Rudnicka, Dominika ^a   Oszmiana, Anna ^b   Finch, Donna K ^c   Strickland, Ian ^c   Schofield, Darren J ^c   Lowe, David C ^c   Sleeman, Matthew A ^c   Davis, Daniel M ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c MEDIMMUNE LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; EPITOPE; FC RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; MEMBRANE PROTEIN; MOESIN; NOCODAZOLE; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; MYOSIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; B LYMPHOCYTE; CAPPING PHENOMENON; CELL SURFACE; CONFOCAL LASER SCANNING MICROSCOPY; CONTROLLED STUDY; CROSS LINKING; DAUDI CELL LINE; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IMMUNOPHARMACOLOGY; MICROTUBULE ORGANIZING CENTER; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAJI CELL LINE; TARGET CELL; CYTOLOGY; ENZYME IMMUNOASSAY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NATURAL KILLER CELL; NEOPLASM; PATHOLOGY; TUMOR CELL CULTURE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; HUMANS; IMMUNOENZYME TECHNIQUES; INTERCELLULAR ADHESION MOLECULE-1; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICROTUBULE-ORGANIZING CENTER; MYOSINS; NEOPLASMS; TUMOR CELLS, CULTURED;

MLCS; MLOWN;

EID: 84881073251     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-02-482570     Document Type: Article

References (27)

1. Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs. 2010;70(11): 1445-1476.
2. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 2002;61(10):883-888.
3. Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997; 90(6):2188-2195.
4. Nadler LM, Ritz J, Hardy R, Pesando JM, Schlossman SF, Stashenko P. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest. 1981;67(1):134-140.
5. Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol. 2003;30(1 Suppl 2):3-8.
6. Mathas S, Rickers A, Bommert K, Dörken B, Mapara MY. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res. 2000;60(24):7170-7176.
7. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000; 6(4):443-446.
8. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754-758.
9. Hubert P, Heitzmann A, Viel S, et al. Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy. Cancer Res. 2011;71(15):5134-5143.
10. Golay J, Manganini M, Facchinetti V, et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica. 2003; 88(9):1002-1012.
11. Eisenbeis CF, Grainger A, Fischer B, et al. Combination immunotherapy of B-cell non-Hodgkin’s lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Clin Cancer Res. 2004;10(18 Pt 1):6101-6110.
12. Gluck WL, Hurst D, Yuen A, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin’s lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res. 2004;10(7):2253-2264.
13. Bowles JA, Wang SY, Link BK, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood. 2006; 108(8):2648-2654.
14. Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101(3):1045-1052.
15. Li Q, Lau A, Morris TJ, Guo L, Fordyce CB, Stanley EF. A syntaxin 1, Galpha(o), and N-type calcium channel complex at a presynaptic nerve terminal: analysis by quantitative immunocolocalization. J Neurosci. 2004;24(16): 4070-4081.
16. Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood. 2002;99(9):3256-3262.
17. Lim SH, Vaughan AT, Ashton-Key M, et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood. 2011;118(9):2530-2540.
18. Deans JP, Robbins SM, Polyak MJ, Savage JA. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J Biol Chem. 1998;273(1):344-348.
19. Polyak MJ, Tailor SH, Deans JP. Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J Immunol. 1998;161(7): 3242-3248.
20. Tsukita S, Yonemura S. Cortical actin organization: lessons from ERM (ezrin/radixin/ moesin) proteins. J Biol Chem. 1999;274(49): 34507-34510.
21. Sánchez-Madrid F, Serrador JM. Bringing up the rear: defining the roles of the uropod. Nat Rev Mol Cell Biol. 2009;10(5):353-359.
22. Millán J, Montoya MC, Sancho D, Sánchez-Madrid F, Alonso MA. Lipid rafts mediate biosynthetic transport to the T lymphocyte uropod subdomain and are necessary for uropod integrity and function. Blood. 2002;99(3):978-984.
23. Li H, Ayer LM, Polyak MJ, et al. The CD20 calcium channel is localized to microvilli and constitutively associated with membrane rafts: antibody binding increases the affinity of the association through an epitope-dependent crosslinking-independent mechanism. J Biol Chem. 2004;279(19):19893-19901.
24. Polyak MJ, Li H, Shariat N, Deans JP. CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins. J Biol Chem. 2008;283(27): 18545-18552.
25. Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol. 1993;121(5): 1121-1132.
26. Walshe CA, Beers SA, French RR, et al. Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. J Biol Chem. 2008;283(25):16971-16984.
27. Franke A, Niederfellner GJ, Klein C, Burtscher H. Antibodies against CD20 or B-cell receptor induce similar transcription patterns in human lymphoma cell lines. PLoS ONE. 2011;6(2):e16596.